Stereotactic Body Radiosurgery (SBR) as treatment for metastatic bladder cancer delivers high dose radiation precisely to the site of cancer. Gil Lederman & his team are expert in it, hence providing treatment to all who need it most.
2. Authored by: Ariel Lederman, Mordecha
Loksen, Thomas Lowinger, Daniel Izon, Gil
Lederman
3. Stereotactic Body Radiosurgery (SBR) as
treatment for metastatic bladder cancer
delivers high dose radiation precisely to the
site of cancer. In our prospective data
analysis, 20 sites of extravesical bladder
cancer treated with SBR were analyzed.
4. Twenty metastatic bladder neoplasms were treated
in 15 patients. Sixteen were transitional cell
carcinoma, 2 adenocarcinoma, 1 squamous cell
carcinoma, and 1 rhabdomyosarcoma. Ages ranged
from 39 to 82 years (mean 64) with 4 females and
11 males. Tumor volumes ranged from 10.2 to 563
cc (mean 129.8 cc). Patients were treated with 500-
900 cGy (median 800) in 5-8 fractions (median 5)
for a total dose of 3000-4500 cGy (median 4000).
5. Cancers were radiographically evaluated with
contrast CT and/or MRI studies and reviewed
independently by radiologists. Disease
control is defined as cessation of growth,
shrinkage or disappearance of the tumor
after treatment.
6. Follow-up ranged from 1 to 20 months
(mean 8 months). The overall control rate was
90%. Both patients who did not respond to
treatment were males with transitional cell
carcinoma. By dose, volume, age, sex and
prior treatment, there was no statistically
significant difference in outcome among the
20 patients treated.
7. SBR for metastatic bladder cancer offers a well-
tolerated, non-invasive technique with a high rate
of tumor control. Patients continue to be evaluated
for longer follow up, possible benefits of local
control and potential survival advantage. SBR
remains an option for those whom standard
approaches have not produced desired results or in
patients seeking an alternative to surgical or
chemotherapeutic treatment.
8. Dr. Gil Lederman has played an essential role in
this treatment as he has studied internal medicine
at the University of Chicago, Michael Reese Hospital
and then went on to study medical oncology and
radiation oncology at Harvard.
Gil Lederman is triple Board certified, and has
lectured around the world, and his expertise has
been sought by tens of thousands. With more than
two decades of experience in Stereotactic
Radiosurgery, Dr. Lederman now treats patients in
an office setting at Radiosurgery New York.
